Oral LGD1057 data

Investigators reported interim results from a Phase I dose escalation trial of the compound, which is being developed by the San Diego company and partner Allergan Inc.

The report at the International Society for Experimental Hematology meeting in Minneapolis included 25 patients who have been treated with single, daily doses of LGD1057 for four weeks at doses up to 230 mg/m2/day. The patients' cancers included non-small cell lung cancer, sarcoma, cutaneous T cell lymphoma, malignant mesothelioma and all-trans-retinoic acid-resistant acute promyelocytic leukemia. Patients have been treated for up to 95 days. ...